We acquire royalty payment rights associated with pre-commercial drug candidates and commercial therapies. Our core focus is on development-stage assets with blockbuster potential that are licensed to and being developed by well-capitalized partners. We also acquire royalties on commercialized therapies that address the needs of specific patient populations.
We understand the value of milestone and royalty rights. For biotech companies, monetizing these assets results in an infusion of non-dilutive, non-recourse capital to fund operations and pursue clinical goals.
If you or your company have a royalty license for a pre-commercial clinical candidate that is in active development with a partner or a commercialized therapy, we are happy to talk with you about how XOMA Royalty may be able to provide you with non-dilutive, non-recourse capital.
